William Blair & Company
NVIV

William Blair & Company’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

William Blair & Company’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3
Closed -$159K – 1582
2017
Q2 		$159K Buy
+3
New +$164K ﹤0.01% 1383

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

William Blair & Company's NVIV Position: Q3 2017 in Review

William Blair & Company sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2017, closing a stake of 3 shares — an estimated $159K sold.

William Blair & Company first reported a position in NVIV in Q2 2017 and held it in 1 quarter. The position peaked at $159K in Q2 2017. 33 funds tracked by Wall St. Rank hold NVIV as of Q3 2017.

  • William Blair & Company reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2017 after selling out during the quarter.
  • William Blair & Company sold 3 InVivo Therapeutics Holdings Corp shares in Q3 2017, an estimated $159K.
  • William Blair & Company first reported a position in InVivo Therapeutics Holdings Corp in Q2 2017 and held it in 1 quarter.
  • William Blair & Company's InVivo Therapeutics Holdings Corp position peaked at $159K in Q2 2017.
  • 33 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2017.

Based on William Blair & Company's 13F filing for Q3 2017, filed 13 Nov 2017.